The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Antiviral therapies are used to help control disease, but they are limited by toxicity and the emergence of viral resistance.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

The Pharma Data

DECEMBER 1, 2020

has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. The distribution of the vaccine in the U.K. View the full release here: [link].

Vaccine 40

Vaccine Clinical Trials Trials Production 40

The Pharma Data

NOVEMBER 9, 2020

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

Drug Discovery World

SEPTEMBER 16, 2022

Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. .

Therapies 130

Therapies Clinical Trials Production Trials 130

The Pharma Data

SEPTEMBER 11, 2020

Starpharma strived to release DEP remdesivir to allow for less frequent dosing and for use in non-hospital settings such as care homes. DEP remdesivir enables subcutaneous or under the skin injections rather than intravenous infusion, allowing for outpatient treatments and reducing the burden on hospitals. Saama Technologies, Inc. ,

Clinical Trials 52

Clinical Trials Pharma Companies Hospitals Trials 52

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 Calquence binds covalently to BTK, thereby inhibiting its activity.4,5 CALAVI US).

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

Drug Discovery World

MARCH 29, 2023

Peter O’Donnell, Applied Clinical Trials’ Brussels Correspondent, summarises this as the EMA being tasked with creating a European network of patient representatives, academics, drug developers, investigators, and centres with expertise in the performance of studies in the paediatric population.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

The Pharma Data

JANUARY 20, 2021

The approval of Verquvo by the FDA, which is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics, is based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority regulatory review. Verquvo (vericiguat) 2.5

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

OCTOBER 27, 2020

Clynes developed several novel therapeutic approaches in cancer and autoimmunity, including DC targeting for cancer vaccines and Syk and JAK mediated inhibition of DCs and T cells in autoimmunity therapy. He is an internationally recognized key opinion leader, clinical investigator and translational research in mesothelioma.

Virus 52

Virus Engineering Clinical Development International 52

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. Diamyd Medical develops therapies for type 1 diabetes.

Drug Development 40

Drug Development Clinical Trials Vaccine Trials 40

The Pharma Data

JULY 21, 2021

mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. VERQUVO is being jointly developed by Merck and Bayer AG. In the EU, VERQUVO (2.5 In the U.S., About Merck.

Treatment 52

Treatment Production Hospitals FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I Non-GAAP EPS of $1.74 Year-to-date results can be found in the attached tables.

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

APRIL 29, 2022

We designed the clinical development program for PAXLOVID to be comprehensive and ambitious with the aim of being able to help combat COVID-19 in a very broad population of patients,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

FDA 52

FDA Trials Treatment Virus 52

The Pharma Data

SEPTEMBER 1, 2020

At the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, Bristol Myers Squibb and collaborators will present 15 clinical and non-clinical abstracts that reinforce the breadth and depth of the company’s research in MS. Presentation Topic: Clinical Trials. Presentation Topic: Disease Modifying Therapies – Risk Management.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

MARCH 23, 2023

Dupixent is the first and only biologic to demonstrate a clinically meaningful and highly significant reduction (30%) in moderate or severe acute exacerbations of COPD (rapid and acute worsening of respiratory symptoms), while also demonstrating significant improvements in lung function, quality of life and COPD respiratory symptoms.

Trials 40

Trials Disease Treatment Therapies 40

The Pharma Data

JUNE 26, 2021

“Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

AUGUST 3, 2021

A recent trial showed a significantly lower risk with empagliflozin of hospitalization for heart failure or cardiovascular death in adult patients with HFpEF. Net sales of the swine vaccine INGELVAC CIRCOFLEX ® continued to recover in many countries with the decline of African swine fever. INGELVAC CIRCOFLEX ® sales grew by 18.1

Research 52

Research Clinical Trials Treatment Production 52

Drug Discovery World

FEBRUARY 28, 2023

mRNA technology helped us to vaccinate the world against SARS-CoV-2. With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to.

Disease 130

Disease Treatment Vaccine DNA 130

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

OCTOBER 29, 2020

. “Patients with alopecia areata deal with unpredictable and long-lasting episodes of hair loss and many don’t find relief from the therapies that are currently used,” said Lotus Mallbris, M.D., vice president of immunology development at Lilly. WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

JULY 29, 2021

Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The Cell Therapy product sales increased 39% to $219 million for the second quarter 2021 compared to the same period in 2020.

Science 52

Science Production Treatment FDA 52

The Pharma Data

APRIL 7, 2022

At Pfizer, we have a strong heritage in, and commitment to, fighting infectious diseases, most recently evidenced by our delivery of the first authorized vaccine and oral therapy to combat COVID-19,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. Sisunatovir has been granted Fast Track designation by the U.S.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

MAY 31, 2022

billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

JUNE 2, 2022

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The number of serotypes in current vaccines is limited due to the degree of immunological interference observed when using existing conjugation technologies.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

JUNE 16, 2021

Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitalized patients with COVID-19 pneumonia . Director of the Academic Research Organization, Hospital Israelita Albert Einstein. in the placebo group. “We

Hospitals 40

Hospitals Clinical Trials Treatment Trials 40

The Pharma Data

JANUARY 18, 2021

IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ The development of BT-001 is progressing well and we are pleased to start this clinical trial in France with patients being enrolled across the country in four reference clinical centers, and in other hospitals in Europe. platform). platform).

Virus 40

Virus Trials Clinical Trials Engineering 40

The Pharma Data

APRIL 7, 2021

XELJANZ has been studied in more than 50 clinical trials worldwide and prescribed to over 208,000 adult patients (the majority of whom were RA patients) worldwide in the last eight years. Patients treated with XELJANZ* are at increased risk for developing serious infections that may lead to hospitalization or death. INDICATIONS.

Treatment 52

Treatment Clinical Trials Therapies Vaccine 52

The Pharma Data

AUGUST 22, 2021

today that the European Commission (EC) has approved XELJANZ ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).

Marketing 52

Marketing Clinical Trials Treatment Therapies 52

The Pharma Data

MARCH 4, 2021

Baricitinib has received Breakthrough Therapy designation from the U.S. vice president of immunology development at Lilly. “We are looking forward to sharing the totality of data from the overall clinical development program for baricitinib as a potential first-in-disease treatment for alopecia areata.”

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

OCTOBER 15, 2020

The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., Axovant – Kristin Vuori was named to the board of directors at Axovant Gene Therapies Ltd.

Pharmaceuticals 52

Pharmaceuticals Clinical Pharmacology Medical Schools Vaccine 52

The Pharma Data

OCTOBER 28, 2020

Our R&D Engine continued to advance our Wave 1 pipeline, with 7 new regulatory filings anticipated within the next 12 months, and we expanded our cell therapy capabilities, both of which will help drive Takeda’s future growth. Press release ). Press release ). Press release ). Press release ). Press release ).

Pharmaceutical Companies 40

Pharmaceutical Companies Engineering Therapies Clinical Trials 40

The Pharma Data

DECEMBER 2, 2020

The new plant will as a first priority produce recombinant GAD65, the active pharmaceutical ingredient in the therapeutic diabetes vaccine Diamyd ® currently in late-stage clinical development. About Diamyd Medical Diamyd Medical develops therapies for type 1 diabetes.

Production 52

Production Vaccine Laboratories Therapies 52